Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.
Por:
Minnema, MC, Krishnan, AY, Berdeja, JG, Rocafiguera, AO, van de Donk, NWCJ, Rodriguez-Otero, P, Morillo, D, Mateos, MV, Costa, LJ, Caers, J, Vishwamitra, D, Ma, J, Yang, S, Hilder, B, Tolbert, JA, Goldberg, JD and Chari, A
Publicada:
1 jun 2022
Resumen:
Filiaciones:
Univ Med Ctr Utrecht, Utrecht, Netherlands.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Hosp Badalona Germans Trias & Pujol, Inst Catal Oncol & Inst Josep Carreras, Badalona, Spain.
Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands.
Clin Univ Navarra, Madrid, Spain.
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain.
Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain.
Univ Alabama Birmingham, Birmingham, AL USA.
Univ Liege, Liege, Belgium.
Janssen Res & Dev, Spring House, PA USA.
Janssen Res & Dev, Raritan, NJ USA.
Mt Sinai Sch Med, New York, NY USA.
|